Amendments to the claims:

This listing of claims replaces all prior versions, and listings, of claims in the application.

Listing of claims:

Claims 1-22 (cancelled).

23 (previously presented): A method of testing blood for reaction to a substance comprising the steps of:

- selecting a cryopreserved unit dose comprising a blood product including viable cells and a cryopreservative from among a plurality of identical cryopreserved unit doses obtained from a single or pooled sample of blood taken from a human or animal;
- thawing the cryopreserved unit dose;
- contacting the thawed, cryopreserved unit dose with the substance; and
- determining, by biological, physical, chemical, or physicochemical means, whether the viable cells in the unit dose react with the substance in an immunofunctional, toxic, or modulatory blood reaction.

24 (previously presented): The method of claim 23 wherein the blood product is leukocytes.

25 (previously presented): The method of claim 23 wherein the blood product is whole blood.

26 (currently amended): The method of claim 23 wherein the blood product further comprises clotting inhibitors, diluents, or a combination thereof.

27 (currently amended): The method of claim 24 wherein the blood product further comprises clotting inhibitors, diluents, or a combination thereof.

28 (currently amended): The method of claim 25 wherein the blood product further comprises clotting inhibitors, diluents, or a combination thereof.

Claims 29-34 (cancelled).

35 (previously presented): A method of testing blood for reaction to a substance comprising the steps of:

- selecting a cryopreserved unit dose comprising a blood product including viable leukocytes and a cryopreservative from among a plurality of identical cryopreserved unit doses obtained from a single or pooled sample of blood taken from a human or animal;
- thawing the cryopreserved unit dose;
- contacting the thawed, cryopreserved unit dose with the substance; and

- determining, by biological, physical, chemical, or physicochemical means, whether the viable leukocytes in the unit dose react with the substance in an immunofunctional, toxic, or modulatory blood reaction.

36 (previously presented): The method of claim 35 wherein the blood product is leukocytes.

37 (previously presented): The method of claim 35 wherein the blood product is whole blood.

38 (currently amended): The method of claim 35 wherein the blood product further comprises clotting inhibitors, diluents, or a combination thereof.

39 (currently amended): The method of claim 36 wherein the blood product further comprises clotting inhibitors, diluents, or a combination thereof.

40 (currently amended): The method of claim 37 wherein the blood product further comprises clotting inhibitors, diluents, or a combination thereof.

41 (new): An *in vitro* method of testing a substance for potentially reacting with blood *in vivo* comprising the steps of:

- selecting a cryopreserved unit dose comprising a blood product including viable cells and a cryopreservative from a collection of multiple identical cryopreserved standardized unit doses obtained from a single or pooled sample of blood taken from a human or animal;
- thawing the cryopreserved unit dose;
- contacting the thawed, cryopreserved unit dose with the substance; and
- determining, by biological, physical, chemical, or physicochemical means, whether the viable cells in the unit dose react with the substance in an immunofunctional, toxic, or modulatory blood reaction.

42 (new): The method of claim 41 wherein the blood product is leukocytes.

43 (new): The method of claim 41 wherein the blood product is whole blood.

44 (new): The method of claim 41 wherein the blood product further comprises clotting inhibitors, diluents, or a combination thereof.

45 (new): The method of claim 42 wherein the blood product further comprises clotting inhibitors, diluents, or a combination thereof.

46 (new): The method of claim 43 wherein the blood product further comprises clotting inhibitors, diluents, or a combination thereof.